LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

Home・Stock List・Denali Therapeutics Inc

Denali Therapeutics Inc

Closed

SectorHealthcare

19.65 1.87

Buy Sell

Overview

Share price change

24h

Current

Min

19.04

Max

19.68

Key metrics
By Trading Economics
Income	102K -128M
EPS	-0.69
Employees	507
EBITDA	-9.8M -135M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+83.46% upside

Dividends
By Dow Jones
Next Earnings	7 Aug 2026

Market Stats
By TradingEconomics
Market Cap	277M 3.2B
Previous open	17.78
Previous close	19.65

News Sentiment

By Acuity

67%

33%

13 / 344 Healthcare

Denali Therapeutics Inc Chart

Past performance is not a reliable indicator of future results.

Related News

3 Jun 2026, 23:22 UTC

Earnings

Major Market Movers

Broadcom Shares Slide Despite Jump in 2Q Revenue on AI Chip Demand -- Update

3 Jun 2026, 23:09 UTC

Hot Stocks

Stocks to Watch: Broadcom, CrowdStrike, PVH, Petco

3 Jun 2026, 20:51 UTC

Earnings

Costco Reports 15% Sales Growth in May

3 Jun 2026, 20:43 UTC

Earnings

Broadcom 2Q Revenue Climbs on AI Chip Demand

3 Jun 2026, 23:48 UTC

Market Talk

Nikkei May Fall Amid Renewed Concerns About Iran Conflict -- Market Talk

3 Jun 2026, 23:48 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

3 Jun 2026, 23:35 UTC

Market Talk

Oil Futures Fall on Possible Technical Correction -- Market Talk

3 Jun 2026, 23:15 UTC

Market Talk

Earnings

Five Below, Broadcom and Crowdstrike Fall Despite Solid Results -- Market Talk

3 Jun 2026, 22:08 UTC

Hot Stocks

After-Hours Stocks to Watch: CrowdStrike, Broadcom, Five Below -- WSJ

3 Jun 2026, 21:54 UTC

Market Talk

Correction to Oil Futures Rise on Concerns About U.S.-Iran Talks Article on June 1

3 Jun 2026, 21:18 UTC

Earnings

Broadcom's Non-AI Semiconductor Revenue Rose 6% in 2Q, CEO Says

3 Jun 2026, 21:15 UTC

Earnings

Broadcom CEO: Google Partnership Continues to Be 'Very Substantial'

3 Jun 2026, 21:13 UTC

Earnings

Broadcom CEO Expects AI Semiconductor Revenue Growth to Continue in Fiscal 2028

3 Jun 2026, 21:13 UTC

Earnings

Broadcom Continues to Expect AI Semiconductor Revenue of More Than $100B in 2027, CEO Says

3 Jun 2026, 21:12 UTC

Earnings

Broadcom Expects AI Semiconductor Revenue of $56B This Year, CEO Says

3 Jun 2026, 21:09 UTC

Earnings

Broadcom CEO: Networking Made Up Almost 40% of AI Revenue in 2Q

3 Jun 2026, 21:03 UTC

Earnings

Broadcom Stock Falls After Earnings. Here's Why. -- Barrons.com

3 Jun 2026, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

3 Jun 2026, 20:43 UTC

Earnings

CrowdStrike Stock Falls Despite Earnings Beat -- Barrons.com

3 Jun 2026, 20:39 UTC

Acquisitions, Mergers, Takeovers

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- 4th Update

3 Jun 2026, 20:37 UTC

Acquisitions, Mergers, Takeovers

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- 3rd Update

3 Jun 2026, 20:35 UTC

Earnings

Broadcom Stock Falls Despite Record Results -- Barrons.com

3 Jun 2026, 20:21 UTC

Acquisitions, Mergers, Takeovers

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- 2nd Update

3 Jun 2026, 20:17 UTC

Earnings

Broadcom 2Q Semiconductor Solutions Revenue $15B >AVGO

3 Jun 2026, 20:17 UTC

Earnings

Broadcom Sees 3Q Semiconductor Revenue From AI $16B >AVGO

3 Jun 2026, 20:15 UTC

Acquisitions, Mergers, Takeovers

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- Update

3 Jun 2026, 20:15 UTC

Earnings

Broadcom 2Q Adj EPS $2.44 >AVGO

3 Jun 2026, 20:15 UTC

Earnings

Broadcom 2Q EPS $1.91 >AVGO

3 Jun 2026, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

3 Jun 2026, 20:15 UTC

Earnings

Broadcom 2Q Rev $22.19B >AVGO

Peer Comparison

Price change

Denali Therapeutics Inc Forecast

Price Target

By TipRanks

83.46% upside

12 Months Forecast

Average 35.5 USD 83.46%

High 42 USD

Low 23 USD

Based on 13 Wall Street analysts offering 12 month price targets forDenali Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

13 ratings

Buy

Hold

Sell

Based on 13 analysts giving stock ratings to Denali Therapeutics Inc - Dist in the past 3 months.

Sentiment

By Acuity

13 / 344 Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Denali Therapeutics Inc

Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.